Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Status:
Unknown status
Trial end date:
2019-12-15
Target enrollment:
Participant gender:
Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10%
BSA who are receiving etanercept or adalimumab for at least 24 weeks